Cargando…

FAK/PYK2 inhibitors defactinib and VS-4718 enhance immune checkpoint inhibitor efficacy

Detalles Bibliográficos
Autores principales:	Ring, Jennifer, Li, Yajuan, Shapiro, Irina, Wang, Yan, Weaver, David, Pachter, Jonathan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4649458/ http://dx.doi.org/10.1186/2051-1426-3-S2-P354

Ejemplares similares

Defactinib inhibits PYK2 phosphorylation of IRF5 and reduces intestinal inflammation
por: Ryzhakov, Grigory, et al.
Publicado: (2021)

Targeting focal adhesion kinase reprograms the pancreatic tumor microenvironment and renders pancreas cancer responsive to checkpoint immunotherapy
por: Jiang, Hong, et al.
Publicado: (2015)

Endogenous Control Mechanisms of FAK and PYK2 and Their Relevance to Cancer Development
por: Naser, Rayan, et al.
Publicado: (2018)

Non-redundant functions of FAK and Pyk2 in intestinal epithelial repair
por: Thomas, Keena S., et al.
Publicado: (2019)

Tumor kinetics prior to treatment correlate with response to checkpoint inhibitors
por: Cadena, Alexandra P, et al.
Publicado: (2015)

Pyk2 and FAK differentially regulate invadopodia formation and function in breast cancer cells
por: Genna, Alessandro, et al.
Publicado: (2018)

VS-4718 Antagonizes Multidrug Resistance in ABCB1- and ABCG2-Overexpressing Cancer Cells by Inhibiting the Efflux Function of ABC Transporters
por: Ji, Ning, et al.
Publicado: (2018)

Molecular Docking, Molecular Dynamics Simulations, and Free Energy Calculation Insights into the Binding Mechanism between VS-4718 and Focal Adhesion Kinase
por: Shi, Mingsong, et al.
Publicado: (2022)

Compensatory role for Pyk2 during angiogenesis in adult mice lacking endothelial cell FAK
por: Weis, Sara M., et al.
Publicado: (2008)

Microglial Cytokines Induce Invasiveness and Proliferation of Human Glioblastoma through Pyk2 and FAK Activation
por: Nuñez, Rebeca E., et al.
Publicado: (2021)

Combination immunotherapy with oncolytic vaccinia virus and checkpoint inhibitor following local tumor irradiation
por: Minev, Boris, et al.
Publicado: (2014)

Targeting of phosphatidylserine by monoclonal antibodies enhances activity of immune checkpoint inhibitors in breast tumors
por: Gong, Jian, et al.
Publicado: (2014)

6. Treatment resistant ulcerating dermatomyositis in metastatic melanoma treated with checkpoint inhibitor therapy
por: Parker, Lucy, et al.
Publicado: (2019)

Enhanced efficacy of IL-15-based ALT-803 superagonist complex in combination with immune checkpoint inhibitors in hematologic and metastatic mouse tumor models
por: Xu, Wenxin, et al.
Publicado: (2014)

Checkpoint inhibitors synergize with therapeutic platforms, ZVex™ and GLAAS™ by enhancing lentiviral vector-induced tumor-specific immunity and adjuvant-mediated anti-tumor efficacy
por: Albershardt, Tina C, et al.
Publicado: (2015)

"Arming" the chimeric oncolytic adenovirus enadenotucirev to deliver checkpoint inhibitors and other therapeutics directly to tumours
por: Champion, Brian R, et al.
Publicado: (2014)

Self-adjuvanted RNActive(® )vaccines provide a promising platform for combination therapies with checkpoint inhibitors
por: Kowalczyk, Aleksandra, et al.
Publicado: (2014)

Inhibition of FAK kinase activity preferentially targets cancer stem cells
por: Kolev, Vihren N., et al.
Publicado: (2017)

Enhanced efficacy of ALT-803, an IL-15-based superagonist complex, in combination with immune checkpoint inhibitors in an orthotopic muscle invasive bladder tumor model in mice
por: Xu, Wenxin, et al.
Publicado: (2015)

Systemic immunotherapy of superficial mouse bladder cancer with Avelumab (MSB0010718C), an anti-PD-L1 immune checkpoint inhibitor
por: Vandeveer, Amanda, et al.
Publicado: (2015)

Non-Overlapping Functions for Pyk2 and FAK in Osteoblasts during Fluid Shear Stress-Induced Mechanotransduction
por: Young, Suzanne R. L., et al.
Publicado: (2011)

Targeting FAK/PYK2 with SJP1602 for Anti-Tumor Activity in Triple-Negative Breast Cancer
por: Jeon, Myeongjin, et al.
Publicado: (2023)

AB093. The efficacy of medical treatment of Peyronie’s disease: Potaba monotherapy vs. combination therapy with Tamoxifen, L-carnitine, and PDE5 inhibitor
por: Park, Jong Jin, et al.
Publicado: (2016)

Poxvirus immunotherapies in combination with immune checkpoint inhibitors synergize to eliminate tumors in a mouse tumor model
por: Foy, Susan P, et al.
Publicado: (2013)

Combination of EP4 antagonist and checkpoint inhibitors promotes anti-tumor effector T cells in preclinical tumor models
por: Bao, Xingfeng, et al.
Publicado: (2015)

Defactinib attenuates osteoarthritis by inhibiting positive feedback loop between H-type vessels and MSCs in subchondral bone
por: Hu, Yanjun, et al.
Publicado: (2020)

FAK/PYK2 promotes the Wnt/β-catenin pathway and intestinal tumorigenesis by phosphorylating GSK3β
por: Gao, Chenxi, et al.
Publicado: (2015)

Pharmacological Inhibition of FAK-Pyk2 Pathway Protects Against Organ Damage and Prolongs the Survival of Septic Mice
por: Alves, Gustavo Ferreira, et al.
Publicado: (2022)

A242 DELAYED STEROID TAPER MAY REDUCE RISK OF RELAPSE IN PATIENTS WITH IMMUNE CHECKPOINT INHIBITOR ASSOCIATED HEPATOTOXICIT
por: Almousawi, F, et al.
Publicado: (2023)

Poxvirus-based active immunotherapy synergizes with immune checkpoint inhibitors to cause tumor regression and extend survival in preclinical models of cancer
por: Foy, Susan P, et al.
Publicado: (2014)

Anticancer effect obtained against MCA205 sarcoma following treatment with the oncolytic peptide LTX-315 in combination with immune checkpoint inhibitors
por: Rekdal, Öystein, et al.
Publicado: (2015)

PYK2 mediates the BRAF inhibitor (vermurafenib)-induced invadopodia formation and metastasis in melanomas
por: Shen, Junling, et al.
Publicado: (2022)

Reasons for using and efficacy of raltegravir in salvage regimens without protease inhibitors in clinical practice
por: Llibre, JM, et al.
Publicado: (2010)

Antibody-mediated blockade of phosphatidylserine enhances the anti-tumor activity of targeted therapy and immune checkpoint inhibitors by affecting myeloid and lymphocyte populations in the tumor microenvironment
por: Yopp, Adam, et al.
Publicado: (2014)

Targeted Inhibition of FAK, PYK2 and BCL-XL Synergistically Enhances Apoptosis in Ovarian Clear Cell Carcinoma Cell Lines
por: Yoon, Heejei, et al.
Publicado: (2014)

Hydrogen Sulfide Recruits Macrophage Migration by Integrin β1-Src-FAK/Pyk2-Rac Pathway in Myocardial Infarction
por: Miao, Lei, et al.
Publicado: (2016)

miR-138 exerts anti-glioma efficacy by targeting immune checkpoints
por: Wei, Jun, et al.
Publicado: (2013)

AurkA inhibitors enhance the effects of B-RAF and MEK inhibitors in melanoma treatment
por: Caputo, Emilia, et al.
Publicado: (2015)

FAK and Pyk2 activity promote TNF-α and IL-1β-mediated pro-inflammatory gene expression and vascular inflammation
por: Murphy, James M., et al.
Publicado: (2019)

Safety and efficacy of biological therapy with TNF-inhibitors and non TNF-inhibitors in a cohort of young adults affected by juvenile idiopathic arthritis (JIA): data from a single centre experience
por: Lorenzo, Ceri, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_a7ka1mgdo0g9shp8cbg5j4h828